​

Supernus Pharmaceuticals Ownership | Who Owns Supernus Pharmaceuticals?

OverviewForecastRevenueFinancialsChartTranscripts

Supernus Pharmaceuticals Ownership Summary

Supernus Pharmaceuticals is owned by 50.44% institutional investors, 4.26% insiders, and 45.30% retail investors. Blackrock is the largest institutional shareholder, holding 18.90% of SUPN shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 5.94% of its assets in Supernus Pharmaceuticals shares.

SUPN Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockSupernus Pharmaceuticals50.44%4.26%45.30%
SectorHealthcare Stocks 42.51%10.81%46.68%
IndustrySpecialty & Generic Drug Manufacturers Stocks26.16%11.89%61.94%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock10.39M18.90%$278.00M
Blackrock funding, inc. /de8.70M15.53%$415.70M
Vanguard group6.04M10.79%$288.88M
Dimensional fund advisors lp3.00M5.36%$143.46M
Armistice capital2.84M5.06%$135.53M
Macquarie group2.53M4.52%$120.98M
State street2.19M3.90%$104.54M
Point72 asset management1.76M3.14%$84.18M
Renaissance1.74M3.11%$83.18M
Geode capital management1.41M2.52%$67.39M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Krensavage asset management363.48K7.40%$17.37M
Quantedge capital pte121.10K3.17%$5.79M
Ashford capital management563.72K3.00%$26.94M
Catalio capital management, lp287.09K2.54%$13.72M
Armistice capital2.84M2.01%$135.53M
Villanova investment management54.87K1.82%$2.62M
Third avenue management189.49K1.71%$9.10M
Rice hall james & associates476.08K1.24%$22.75M
Bruce82.11K1.22%$3.92M
S&t bank/pa88.92K1.19%$4.25M

Top Buyers

HolderShares% AssetsChange
Point72 asset management1.76M0.14%1.25M
Woodline partners lp1.26M0.28%490.83K
Ubs group540.12K0.00%312.77K
Catalio capital management, lp287.09K2.54%287.09K
Goldman sachs group1.16M0.01%266.67K

Top Sellers

HolderShares% AssetsChange
Armistice capital2.84M2.01%-1.98M
Polar capital---1.00M
Blackrock funding, inc. /de8.70M0.01%-669.48K
Aristotle capital boston305.27K0.75%-503.12K
Sofinnova investments377.07K0.99%-422.19K

New Positions

HolderShares% AssetsChangeValue
Catalio capital management, lp287.09K2.54%287.09K$13.72M
Norges bank125.55K0.00%125.55K$4.54M
Quantedge capital pte121.10K3.17%121.10K$5.79M
Ruffer llp55.38K0.15%55.38K$2.65M
Vela investment management40.25K0.47%40.25K$1.92M

Sold Out

HolderChange
Claris advisors, llc / mo /-1.00
Global financial private client-3.00
Larson financial group-5.00
Mendota financial group-5.00
Stephens consulting-10.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2025175-38.60%28,258,627-50.30%500.49%77-51.88%65-18.75%
Jun 30, 2025290-59,380,9950.51%1050.95%16311.64%80-15.79%
Mar 31, 2025286-2.72%59,007,517-0.81%1050.91%144-1.37%93-2.11%
Dec 31, 2024137-49.63%29,073,367-51.31%520.45%69-48.51%37-58.89%
Sep 30, 202427211.02%59,712,0472.23%1080.96%13415.52%9012.50%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF3.33M5.94%-
Delaware Small Cap Core I2.00M3.62%-12.37K
Macquarie Small Cap Core I1.94M3.46%-145.53K
Vanguard Total Stock Mkt Idx Inv1.68M3.00%-35.29K
Vanguard US Total Market Shares ETF1.68M3.00%1.91K
iShares Russell 2000 ETF1.31M2.33%-
Vanguard Small Cap Index1.29M2.30%-8.71K
Stephens SMID Select Growth1.13M2.01%-112.59K
Polar Capital Biotech S Inc1.00M1.79%-175.00K
Vanguard Explorer Inv905.65K1.62%-90.04K

Recent Insider Transactions

DateNameRoleActivityValue
Oct 09, 2025Khattar Jack A. President, CEOSell$78.68K
Oct 09, 2025Khattar Jack A. President, CEOSell$2.95M
Oct 09, 2025NEWHALL CHARLES W III-Sell$1.21M
Oct 09, 2025NEWHALL CHARLES W III-Sell$61.86K
Oct 02, 2025Khattar Jack A. President, CEOSell$91.51K

Insider Transactions Trends

DateBuySell
2025 Q4-6
2025 Q3-21
2025 Q2--
2025 Q1-3
2024 Q4-8

SUPN Ownership FAQ

Who Owns Supernus Pharmaceuticals?

Supernus Pharmaceuticals shareholders are primarily institutional investors at 50.44%, followed by 4.26% insiders and 45.30% retail investors. The average institutional ownership in Supernus Pharmaceuticals's industry, Specialty & Generic Drug Manufacturers Stocks, is 26.16%, which Supernus Pharmaceuticals exceeds.

Who owns the most shares of Supernus Pharmaceuticals?

Supernus Pharmaceuticals’s largest shareholders are Blackrock (10.39M shares, 18.90%), Blackrock funding, inc. /de (8.7M shares, 15.53%), and Vanguard group (6.04M shares, 10.79%). Together, they hold 45.22% of Supernus Pharmaceuticals’s total shares outstanding.

Does Blackrock own Supernus Pharmaceuticals?

Yes, BlackRock owns 18.90% of Supernus Pharmaceuticals, totaling 10.39M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 278M$. In the last quarter, BlackRock increased its holdings by 30.28K shares, a 0.29% change.

Who is Supernus Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Krensavage asset management is Supernus Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 7.40% of its assets in 363.48K Supernus Pharmaceuticals shares, valued at 17.37M$.

Who is the top mutual fund holder of Supernus Pharmaceuticals shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Supernus Pharmaceuticals shares, with 5.94% of its total shares outstanding invested in 3.33M Supernus Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools